JP7721630B2 - 生物活性が低下した抗体バリアント - Google Patents

生物活性が低下した抗体バリアント

Info

Publication number
JP7721630B2
JP7721630B2 JP2023501876A JP2023501876A JP7721630B2 JP 7721630 B2 JP7721630 B2 JP 7721630B2 JP 2023501876 A JP2023501876 A JP 2023501876A JP 2023501876 A JP2023501876 A JP 2023501876A JP 7721630 B2 JP7721630 B2 JP 7721630B2
Authority
JP
Japan
Prior art keywords
antibody
nemolizumab
seq
chromatography
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501876A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023120561A1 (https=
JPWO2023120561A5 (https=
Inventor
健作 細口
愛 原
宗太 増田
美智 ▲高▼城
周介 南部
久美 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2023120561A1 publication Critical patent/JPWO2023120561A1/ja
Priority to JP2023134673A priority Critical patent/JP7812826B2/ja
Publication of JPWO2023120561A5 publication Critical patent/JPWO2023120561A5/ja
Application granted granted Critical
Publication of JP7721630B2 publication Critical patent/JP7721630B2/ja
Priority to JP2026012833A priority patent/JP2026063423A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023501876A 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント Active JP7721630B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023134673A JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021207714 2021-12-22
JP2021207714 2021-12-22
PCT/JP2022/047035 WO2023120561A1 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023134673A Division JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント

Publications (3)

Publication Number Publication Date
JPWO2023120561A1 JPWO2023120561A1 (https=) 2023-06-29
JPWO2023120561A5 JPWO2023120561A5 (https=) 2023-11-22
JP7721630B2 true JP7721630B2 (ja) 2025-08-12

Family

ID=86902603

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023501876A Active JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント
JP2023134673A Active JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023134673A Active JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Country Status (7)

Country Link
US (1) US20250163163A1 (https=)
EP (1) EP4455163A4 (https=)
JP (3) JP7721630B2 (https=)
KR (2) KR102902883B1 (https=)
CN (1) CN118613503A (https=)
TW (1) TW202340249A (https=)
WO (1) WO2023120561A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN119161488A (zh) * 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
医薬品の一般的名称について, 薬生薬審発0703第4号 平成30年7月3日, 2018, [online], [retrieved on 2023.02.17], <URL: http://www.nihs.go.jp/dbcb/JAN/JAN-H30-7-3-2.pdf>
宮原佑弥ほか, 質量分析法を用いたバイオ医薬品の一次および高次構造解析, ファルマシア, 2020, vol. 56, no. 7, pp. 627-631

Also Published As

Publication number Publication date
KR102902883B1 (ko) 2025-12-22
JPWO2023120561A1 (https=) 2023-06-29
JP7812826B2 (ja) 2026-02-10
CN118613503A (zh) 2024-09-06
JP2026063423A (ja) 2026-04-10
WO2023120561A1 (ja) 2023-06-29
JP2023159309A (ja) 2023-10-31
EP4455163A1 (en) 2024-10-30
KR20240117039A (ko) 2024-07-31
TW202340249A (zh) 2023-10-16
KR20260007630A (ko) 2026-01-14
EP4455163A4 (en) 2025-12-24
US20250163163A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7716441B2 (ja) 獣医用抗ｉｌ－３１抗体
CN104364264B (zh) 犬源化抗ngf抗体和其方法
EP3250593B1 (en) Anti-transthyretin antibodies
AU2016223095B2 (en) Antibodies to tau and uses thereof
US20220127356A1 (en) Trem2 antibodies and uses thereof
JP2024063118A (ja) 獣医学使用のためのインターロイキン３１モノクローナル抗体
JP2020185009A (ja) 抗トランスサイレチン抗体
EP3250594B1 (en) Anti-transthyretin antibodies
JP7812826B2 (ja) 生物活性が低下した抗体バリアント
AU2018345807A1 (en) Methods of detecting transthyretin
KR102578087B1 (ko) 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
WO2023108115A1 (en) Ph-selective antibody fc domains
HK40108969A (zh) 生物学活性降低的抗体变体
KR20260058849A (ko) 항-tslp 항체 작제물 및 이의 용도
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies
HK1240249B (en) Anti-transthyretin antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230202

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230912

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150